Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/7/2026 | $50.00 | Outperform | Oppenheimer |
| 1/22/2026 | $42.00 | Outperform | Oppenheimer |
| 1/8/2026 | $40.00 | Strong Buy | Raymond James |
| 1/6/2026 | $35.00 | Buy | H.C. Wainwright |
| 12/1/2025 | $42.00 | Outperform | Leerink Partners |
| 12/1/2025 | $36.00 | Overweight | Morgan Stanley |
| 12/1/2025 | Outperform | William Blair | |
| 12/1/2025 | $40.00 | Outperform | Evercore ISI |
4 - Evommune, Inc. (0002044725) (Issuer)
Company to showcase expansion opportunity for EVO756 (MRGPRX2 Antagonist) into third indication of migraine prophylaxis; Phase 2b study to initiate in 3Q26 Evommune, Inc. (NYSE:EVMN) ("Evommune" or the "Company"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced it will host a webinar highlighting the migraine treatment landscape and the role of MRGPRX2 inhibition on this debilitating condition on Monday, April 13, 2026, at 11:00 a.m. PT (2:00 p.m. ET). The event will include presentations from members of Evommune's management team and the following two leading experts in migraine: Stewart
– Reported positive top-line data from Phase 2a proof-of-concept (POC) trial of EVO301 in atopic dermatitis (AD) – EVO756 on track to report Phase 2b top-line data in chronic spontaneous urticaria (CSU) and AD in 2Q26 and 2H26, respectively – Strengthened balance sheet with $125 million private placement to support additional clinical milestones and extend runway through 2028 Evommune, Inc. (NYSE:EVMN) ("Evommune" or the "Company"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.
Evommune, Inc. ("Evommune" or the "Company") (NYSE:EVMN), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that it has entered into a securities purchase agreement to sell 4,494,279 shares of its common stock to a select group of new and existing mutual funds and dedicated healthcare institutional investors in a private placement. The purchase price of each share of common stock is $27.88. Evommune anticipates the gross proceeds from the private placement to be approximately $125 million, before deducting any transaction-related expenses. The private placement is expected to close on or about Feb
424B3 - Evommune, Inc. (0002044725) (Filer)
DEFA14A - Evommune, Inc. (0002044725) (Filer)
DEF 14A - Evommune, Inc. (0002044725) (Filer)
4 - Evommune, Inc. (0002044725) (Issuer)
4 - Evommune, Inc. (0002044725) (Issuer)
4 - Evommune, Inc. (0002044725) (Issuer)
Oppenheimer resumed coverage of Evommune with a rating of Outperform and set a new price target of $50.00
Oppenheimer initiated coverage of Evommune with a rating of Outperform and set a new price target of $42.00
Raymond James initiated coverage of Evommune with a rating of Strong Buy and set a new price target of $40.00
- Trial met primary efficacy endpoint at week 12 - EVO301 produced rapid, statistically significant EASI reductions at weeks 4, 8 and 12 versus placebo - 33% placebo-adjusted improvement in EASI at week 12 - 23% of EVO301 patients achieved IGA 0/1 at week 12 - Company to hold conference call and webcast at 8:30 a.m. ET today Evommune, Inc. (NYSE:EVMN) (the "Company" or "Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced positive top-line results from its randomized, double-blind, placebo-controlled Phase 2a trial evaluating EVO301. This long-acting fusion protein consisting of